AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1354085 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg
Number of subjects: 134
Study 1354085 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 134
Study 1354085 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 134
Study 1354085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 6380564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage (n = 96)
Number of subjects: 194
Study 6380564 — intervention group
Group type: COMPARATOR
Intervention: No cervical cerclage (n = 98)
Number of subjects: 194
Study 31025274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (anti-PD-1 and anti-CXCR4)
Number of subjects: 0
Study 31025274 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31025274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1
Number of subjects: 0
Study 31025274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CXCR4
Number of subjects: 0
Study 30341023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture focused on the points in the pudendal nerve distribution area (Group 1a)
Number of subjects: 51
Study 30341023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture focused on traditional (distal) meridian points (Group 1b)
Number of subjects: 51
Study 30341023 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (Group 2)
Number of subjects: 51
Study 30341023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (both Group 1a and Group 1b)
Number of subjects: 51
Study 27101379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with Village Health Teams (VHTs) conducting two prenatal and one postnatal home visit, and mobile phone consultations with health workers.
Number of subjects: 1385
Study 27101379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with VHTs conducting home visits and consultations.
Number of subjects: 1385
Study 24504098 — intervention group
Group type: COMPARATOR
Intervention: Aganirsen (0.86 mg/g)
Number of subjects: 12
Study 24504098 — intervention group
Group type: COMPARATOR
Intervention: Aganirsen (1.72 mg/g)
Number of subjects: 12
Study 24504098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aganirsen
Number of subjects: 12
Study 22873635 — intervention group
Group type: EXPERIMENTAL
Intervention: In sequence computer tutorial (e.g. FWS patient + FWS tutorial)
Number of subjects: 92
Study 22873635 — intervention group
Group type: COMPARATOR
Intervention: Out-of-sequence computer tutorial (e.g. FWS patient + ORS tutorial)
Number of subjects: 92
Study 20972956 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (group S)
Number of subjects: 28
Study 20972956 — intervention group
Group type: COMPARATOR
Intervention: Conventional training only (group C)
Number of subjects: 28
Study 20972956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 60 endoscopic examinations
Number of subjects: 28
Study 20972956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 10 and 60 endoscopies
Number of subjects: 28
Study 17118996 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt
Number of subjects: 569
Study 17118996 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg iodine as oral iodized oil
Number of subjects: 569
Study 17118996 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg iodine as oral iodized oil (two doses)
Number of subjects: 569
Study 17118996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 16369066 — intervention group
Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 39
Study 16369066 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 39
Study 12164886 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 9
Study 12164886 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 9
Study 12164886 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 9
Study 12164886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg
Number of subjects: 9
Study 12164886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (optimal doses of lisinopril and losartan)
Number of subjects: 9
Study 10204938 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of morphine (1 ml) and 9 ml of saline
Number of subjects: 437
Study 10204938 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of bupivacaine (2.5 mg/ml)
Number of subjects: 437
Study 10204938 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of saline
Number of subjects: 437
Study 10204938 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of morphine (1 ml) and 9 ml of bupivacaine (2.5 mg/ml)
Number of subjects: 437
Study 7539933 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aids
Number of subjects: 0
Study 7539933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive strategy
Number of subjects: 0
Study 7539933 — intervention group
Group type: COMPARATOR
Intervention: Control (no augmented information)
Number of subjects: 0
Study 2155948 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK 100 mg
Number of subjects: 12
Study 2155948 — intervention group
Group type: EXPERIMENTAL
Intervention: conventional metoprolol 100 mg
Number of subjects: 12
Study 2155948 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 12
Study 2155948 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7006073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with intact influenza vaccine
Number of subjects: 21
Study 7006073 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 21
Study 27406943 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of enteral nutrition formulas (2 different formulas)
Number of subjects: 15
Study 27406943 — intervention group
Group type: COMPARATOR
Intervention: 15 g lactulose
Number of subjects: 15
Study 27406943 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative fructan assay with additional enzymes
Number of subjects: 15
Study 27406943 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic assay for GOS
Number of subjects: 15
Study 25515208 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymosin added to milk
Number of subjects: 125
Study 25515208 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to milk
Number of subjects: 125
Study 22921821 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital international normalized ratio self-testing instruction
Number of subjects: 200
Study 22921821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 21516022 — intervention group
Group type: EXPERIMENTAL
Intervention: IV anti-D (50 μg/kg)
Number of subjects: 25
Study 21516022 — intervention group
Group type: COMPARATOR
Intervention: IVIG (0.8 to 1 g/kg)
Number of subjects: 25
Study 19920236 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d)
Number of subjects: 6837
Study 19920236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6837
Study 16972106 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 7.5 mg/70 kg
Number of subjects: 0
Study 16972106 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 15 mg/70 kg
Number of subjects: 0
Study 16972106 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine 0 mg/70 kg (placebo)
Number of subjects: 0
Study 14740785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone hydrochloride after 6 days of fluticasone propionate (treatment C)
Number of subjects: 12
Study 14740785 — intervention group
Group type: COMPARATOR
Intervention: Intranasal hydromorphone hydrochloride without allergic rhinitis treatment (treatment B)
Number of subjects: 12
Study 14740785 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydromorphone hydrochloride 2.0 mg (treatment A)
Number of subjects: 12
Study 14740785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal treatments (B and C)
Number of subjects: 12
Study 14740785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hydromorphone hydrochloride
Number of subjects: 12
Study 11460278 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing antiseptic mouthrinse (Listerine Antiseptic)
Number of subjects: 34
Study 11460278 — intervention group
Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 34
Study 9377282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.05%
Number of subjects: 60
Study 9377282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.1%
Number of subjects: 60
Study 9377282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 60
Study 9377282 — intervention group
Group type: COMPARATOR
Intervention: Natamycin 5%
Number of subjects: 60
Study 8463939 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 12
Study 8463939 — intervention group
Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 12
Study 8463939 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste brushing after rinsing
Number of subjects: 12
Study 8463939 — intervention group
Group type: EXPERIMENTAL
Intervention: Other commercial rinses
Number of subjects: 12
Study 3010011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nabilone (1 mg 8 hourly)
Number of subjects: 32
Study 3010011 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide (1 mg kg‐1 3 hourly)
Number of subjects: 32
Study 31741069 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management system for diabetes developed with User Centered Design Principles
Number of subjects: 20
Study 29287658 — intervention group
Group type: EXPERIMENTAL
Intervention: AcceleDent Aura appliance
Number of subjects: 40
Study 29287658 — intervention group
Group type: COMPARATOR
Intervention: No appliance
Number of subjects: 40
Study 27220537 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Humidified High-Flow Nasal Cannula (HHHFNC)
Number of subjects: 101
Study 27220537 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 101
Study 24901089 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF (oat β‐glucan 7.5 g, 500 mL, 500 Kcal)
Number of subjects: 30
Study 22830971 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled chia seed (25 g/day for 10 weeks)
Number of subjects: 62
Study 22830971 — intervention group
Group type: COMPARATOR
Intervention: Whole chia seed (25 g/day for 10 weeks)
Number of subjects: 62
Study 22830971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (poppy seed, 25 g/day for 10 weeks)
Number of subjects: 62
Study 19410693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Number of subjects: 15
Study 19410693 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 15
Study 17461474 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily) and Domperidone (10 mg three times daily)
Number of subjects: 198
Study 16036039 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Number of subjects: 0
Study 12113287 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day alpha-tocopherol supplementation
Number of subjects: 18
Study 12113287 — intervention group
Group type: COMPARATOR
Intervention: Control group (not supplemented)
Number of subjects: 18
Study 9441572 — intervention group
Group type: COMPARATOR
Intervention: 1-month, full-time rotation in interviewing and related psychosocial topics
Number of subjects: 63
Study 8088061 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 42
Study 8088061 — intervention group
Group type: COMPARATOR
Intervention: Gold Sodium Thiomalate (GST)
Number of subjects: 42
Study 2800995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with intravenous ketamine for maintenance
Number of subjects: 30
Study 2800995 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with halothane for maintenance
Number of subjects: 30
Study 2800995 — intervention group
Group type: COMPARATOR
Intervention: Halothane for both induction and maintenance
Number of subjects: 30
Study 790959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin prophylaxis
Number of subjects: 93
Study 790959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 30796528 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Collaborative Care Model (SCCM) including group-level interventions (START intervention, Empowerment/Gender-sensitive/Peer to peer) and digital treatment approaches (Smartphone application)
Number of subjects: 0
Study 30796528 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 0
Study 31669971 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐FAIF
Number of subjects: 96
Study 31669971 — intervention group
Group type: COMPARATOR
Intervention: SMAPF
Number of subjects: 96
Study 29199566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose supplement (HD) group
Number of subjects: 96
Study 29199566 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose supplement (LD) group
Number of subjects: 96
Study 29199566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) group
Number of subjects: 96
Study 25458669 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes specific formula (Nutren Diabetes, Nestlé Health Science, Switzerland)
Number of subjects: 0
Study 25458669 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric meal (Cornflakes and milk)
Number of subjects: 0
Study 22276649 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin-based sealant with Er:YAG + AE preparation technique
Number of subjects: 80
Study 22276649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic sealant
Number of subjects: 80
Study 22276649 — intervention group
Group type: COMPARATOR
Intervention: Conventional resin-based sealant
Number of subjects: 80
Study 21190996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days)
Number of subjects: 781
Study 21190996 — intervention group
Group type: COMPARATOR
Intervention: Multiagent chemotherapy (CT)
Number of subjects: 781
Study 21190996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC)
Number of subjects: 781
Study 18036904 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft surgery
Number of subjects: 201
Study 18036904 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass graft surgery
Number of subjects: 201
Study 16110019 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 200 mg daily for 21 days in a 28-day cycle
Number of subjects: 105
Study 16110019 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 50 mg daily for 21 days in a 28-day cycle
Number of subjects: 105
Study 11932085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (IAL)
Number of subjects: 54
Study 11932085 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine/diazepam (IVMD)
Number of subjects: 54
Study 10910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 75
Study 10910653 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled beside the mother
Number of subjects: 75
Study 10910653 — intervention group
Group type: COMPARATOR
Intervention: Swaddled and separated from the mother
Number of subjects: 75
Study 8553820 — intervention group
Group type: EXPERIMENTAL
Intervention: biodegradable self‐reinforced polyglycolide screws
Number of subjects: 29
Study 8553820 — intervention group
Group type: COMPARATOR
Intervention: metallic implants
Number of subjects: 29
Study 2653416 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of social support service by family workers
Number of subjects: 0
Study 2653416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no social support service)
Number of subjects: 0
Study 90354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with adriamycin
Number of subjects: 117
Study 90354 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy without adriamycin
Number of subjects: 117
Study 31682147 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 43
Study 31682147 — intervention group
Group type: COMPARATOR
Intervention: Standardized Episodic Thinking (SET)
Number of subjects: 43
Study 31819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Productivity losses due to P. vivax malaria
Number of subjects: 0
Study 31819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of fluorescent spot test for P. vivax malaria
Number of subjects: 0
Study 28056902 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation of students' hat use during recess and lunch
Number of subjects: 20
Study 28056902 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct observation of teachers' use of sun protective measures
Number of subjects: 20
Study 28056902 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of sunscreen consumption by students
Number of subjects: 20
Study 25041333 — intervention group
Group type: EXPERIMENTAL
Intervention: LTPP (one session/week)
Number of subjects: 272
Study 25041333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (LTPP + fluoxetine)
Number of subjects: 272
Study 25041333 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine treatment (20‐60 mg/day)
Number of subjects: 272
Study 23733915 — intervention group
Group type: EXPERIMENTAL
Intervention: High free fatty acid (FFA) levels (intralipid/heparin-infusion)
Number of subjects: 18
Study 23733915 — intervention group
Group type: COMPARATOR
Intervention: Low free fatty acid (FFA) levels (hyperinsulinemic-euglycemic clamping)
Number of subjects: 18
Study 21569237 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic record‐based intervention with electronic prompts to promote adherence with evidence‐based standards
Number of subjects: 0
Study 21569237 — intervention group
Group type: COMPARATOR
Intervention: Control group (family practices without the intervention)
Number of subjects: 0
Study 19228620 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus stenting
Number of subjects: 951
Study 19228620 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 951
Study 16523837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 IOL
Number of subjects: 32
Study 16523837 — intervention group
Group type: COMPARATOR
Intervention: Acrysof MA60BM IOL
Number of subjects: 32
Study 16523837 — intervention group
Group type: COMPARATOR
Intervention: Sensar Optiedge AR40e IOL
Number of subjects: 32
Study 15083317 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy cookies (52 mg isoflavones)
Number of subjects: 14
Study 15083317 — intervention group
Group type: COMPARATOR
Intervention: Soy-free cookies (no isoflavones)
Number of subjects: 14
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements including coronary calcium measurement using computed tomography
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of ventricular mass and function using cardiac magnetic resonance imaging
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of flow-mediated brachial artery endothelial vasodilation
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of carotid intimal-medial wall thickness and distensibility of the carotid arteries using ultrasonography
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of peripheral vascular disease using ankle and brachial blood pressures
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments of microalbuminuria, standard CVD risk factors, sociodemographic factors, life habits, and psychosocial factors
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples for biochemical risk factors and genetic studies
Number of subjects: 6500
Study 12397006 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up through 2008 for identification and characterization of CVD events
Number of subjects: 6500
Study 9806658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose megestrol acetate (160 mg/day)
Number of subjects: 148
Study 9806658 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose megestrol acetate (640 mg/day)
Number of subjects: 148
Study 9806658 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA hazard score
Number of subjects: 148
Study 9806658 — intervention group
Group type: EXPERIMENTAL
Intervention: Average relative velocity of PSA
Number of subjects: 148
Study 7714514 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 7714514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention treatment
Number of subjects: 0
Study 7714514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7714514 — intervention group
Group type: COMPARATOR
Intervention: Supportive clinical management
Number of subjects: 0
Study 2622988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 12
Study 2622988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (10 hr TIB)
Number of subjects: 12
Study 2622988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2622988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg) after sleep extension
Number of subjects: 12
Study 402406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium nasal solution (4% aqueous solution)
Number of subjects: 104
Study 31369675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment (CH) started at age 7.8 years (Early Group - EG)
Number of subjects: 67